Skip to main content

Table 1 Clinical and demographic baseline characteristics of rheumatoid arthritis patients a

From: Smoking in combination with antibodies to cyclic citrullinated peptides is associated with persistently high levels of survivin in early rheumatoid arthritis: a prospective cohort study

Patient demographics (N = 339)

Level and frequency

Age, years

56.5 ± 16

Women

224 (66%)

Disease duration, months

6.2 ± 3.3

RF+

184 (55%)

aCCP+

169 (49%)

DAS28

5.6 ± 1.26

VAS pain, mm

45 ± 24

HAQ

1.00 ± 0.66

SHS, median (IQR)

1.7 (0 to 5)

Smoking habits

 

   Never

166 (49%)

   Previous

89 (26%)

   Current

84 (25%)

Treatment at start

 

   MTX

131 (39%)

   SLZ

112 (33%)

   Combination of DMARDs

3 (1%)

   No DMARDs

51 (15%)

   Prednisolone

210 (62%)

  1. aaCCP+, positive for antibodies against cyclic citrullinated peptides; DAS28, Disease Activity Score based on evaluation of 28 joints; DMARD, disease-modifying antirheumatic drug; HAQ, Health Assessment Questionnaire; MTX, methotrexate; RF+, rheumatoid factor–positive; SHS, Sharp-van der Heijde score; SLZ, sulphasalazine; VAS, Visual Analogue Scale. The values are mean ± SD or n (%) unless otherwise stated.